(Q36099415)

12 August 2017

1 reference

title

Emerging and potential therapies for osteoporosis (English)

1 reference

12 August 2017

Andrew Grey

1

1 reference

PubMed ID

15833058

12 August 2017

Ian R Reid

series ordinal

2

1 reference

PubMed ID

15833058

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

3

1 reference

12 August 2017

265-278

1 reference

Epidemiology and outcomes of osteoporotic fractures

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

SERMs: current status and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Association of the G-174C variant in the interleukin-6 promoter region with bone loss and fracture risk in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Tibolone for postmenopausal women: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Targeting protein kinases for bone disease: discovery and development of Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

A Src SH2 selective binding compound inhibits osteoclast-mediated resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Chloride channels of intracellular organelles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

21 January 2018

Nitric oxide and bone

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Endothelial nitric oxide synthase in the control of osteoblastic mineralizing activity and bone integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Osteoblast apoptosis and bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Parathyroid hormone as a therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Mechanisms of action and therapeutic potential of strontium in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Stimulation of bone formation in vitro and in rodents by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

The role of statins as potential targets for bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Leptin regulates bone formation via the sympathetic nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Effects of propranolol on bone metabolism in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Inhibition of Bone Resorption in Tissue Culture by Membrane-Stabilizing Drugs*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Sympathetic nervous system as transmitter of mechanical loading in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Use of beta-blockers and risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

High bone mass in mice expressing a mutant LRP5 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

MEPE has the properties of an osteoblastic phosphatonin and minhibin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.3.265

10.1517/13543784.14.3.265

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15833058